Indivi
Guilhem Dupont is the Chairman & CEO at Indivi since September 2012. Prior to that, Guilhem worked as the GLOBAL PRODUCT LEADER - PSYCHIATRY FRANCHISE at Roche from 2010 to 2012, and as the PRODUCT LEADER - EU & USA - SCHIZOPHRENIA FRANCHISE at Janssen, Pharmaceutical Companies of Johnson and Johnson from 2002 to 2010. Guilhem also has experience as a PRODUCT LEADER at Danone from 1998 to 2000. Guilhem holds an MBA from the University of Warwick - Warwick Business School and a Bachelor of Science degree from the University of Kent. Additionally, Guilhem has completed a program in Business school, Management, and marketing at the European Institute of Entrepreneur.
This person is not in any teams
Indivi
1 followers
Indivi is a leading Medtech for the development of digital measurements > biomarkers in neuroscience, headquartered in Basel, Switzerland. Indivi is committed to developing and validating transformative digital endpoints to accelerate and de-risk drug development in neurodegenerative diseases, with a focus on multiple sclerosis, Parkinson’s and Alzheimer’s diseases. Through its exclusive partnership with Basel University Faculty of Medicine and the Research Center for Clinical Neuroimmunology and Neuroscience in Basel (RC2NB), Indivi is dedicated to unlocking the potential of digital endpoints and precision medicine in drug development by creating a fertile symbiotic intersection of knowledge in Data Science, Clinical Science and Advanced Analytics (including machine learning and so-called artificial intelligence).